EV Group successfully finalises an investment in Cornelius Group plc through a minority equity stake.
9.1.2025 15:33:00 EET | Business Wire | Press release
EV Group, a leading specialty chemicals and food ingredients distributor and manufacturer, and Cornelius Group (Cornelius), an international manufacturer and distributor of specialty additives and ingredients to the life sciences and performance chemicals markets, announce today that they have reached binding agreements for the acquisition by EV of a minority stake in Cornelius.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250109291745/en/
Photographed (Left to Right): Darren Spiby, Joint CEO, Cornelius Group plc; Phillip Gibbons, Joint CEO, Cornelius Group plc; Dr Neville Prior, Group Chairman, Cornelius Group plc; Ludovico Balbo di Vinadio, Shareholder and Deputy Chairman, EV Group; Cristina Colombo, Chief Financial Officer, EV Group; Gabriele Bonomi, Chief Executive Officer, EV Group. (Photo: Business Wire)
Under the terms of the transaction, EV Group will increase its stake in Cornelius through additional equity acquisitions of Cornelius shares over the next two to three years.
Founded in 1935 by Dr Ernst Gustav Cornelius in London, Cornelius has a long history as a privately held European chemical manufacturer and distributor, and boasts an international reputation for its capabilities and technical expertise. Over the years, Cornelius has become the partner of choice for many international and local manufacturers in a variety of industries. Currently, Cornelius employs around 100 people and, in the financial year to 31 January 2024, generated a turnover of £42 million.
This partnership between EV Group and Cornelius Group will strengthen both businesses, leveraging their shared technical expertise and complementary strengths. For EV Group, Cornelius provides an established route to market in the UK and Poland, while Cornelius gains access to a broader range of products across manufacturing and distribution. Together, this collaboration will drive growth and support the delivery of Cornelius’ future vision.
The combined business will integrate EV Group's brand lines with Cornelius' offerings, creating a stronger portfolio of commercialised solutions across Life Sciences, Industrial, Medical, and Nutrition markets. With enhanced assets, expanded commercial infrastructure, and deep financial resources, the business is well-positioned to unlock new market opportunities.
Phillip Gibbons, CEO of Cornelius, said: “This partnership reinforces Cornelius’ position and provides the stability needed to execute our vision for the future. I have long admired EV’s entrepreneurial spirit and solid expertise in the chemical distribution sector, and I am delighted they so clearly support our long-term ambitions.”
Gabriele Bonomi, CEO of EV Group, commented: “We are delighted to invest in Cornelius Group to reinforce their position and support the growth of EV. Cornelius perfectly fits in with our strategy; it significantly enhances our capabilities and enriches our product portfolio. It further enhances our international presence.”
Cornelius will continue to focus on its core activities of providing innovative and sustainable solutions in the fields of Performance Chemicals, Life Sciences and the Ocular industry. The management of Cornelius will continue to lead the company to post-completion of this transaction.
EVGROUP
Founded in 1910, Eigenmann & Veronelli Group is an international solutions provider of specialty chemicals and food ingredients. Headquartered in Rho, Italy, EV has a direct presence in Italy, Iberia, Turkey, and the U.A.E. and a commercial reach in more than 40 countries. In 2024, EV generated a consolidated turnover of 347 million euros with more than 350 employees. With over a century of experience, EV is synonymous with effectiveness and efficiency, combining local market knowledge with chemical innovations, and offering a high-quality and diversified portfolio of specialty chemicals and food ingredients as well as tailor-made application, marketing and supply chain solutions, technical and formulation support, and comprehensive regulatory know-how for a wide range of industries.
Follow us on LinkedIn.
CORNELIUS GROUP
Cornelius Group is an independent manufacturer and distributor of raw materials, ingredients and specialty chemicals for life science, performance chemicals and ocular sector operating in UK, Europe, Asia and USA. The core business values: We Lead, We Care, We Deliver are at the heart of the vision, strategy and everyday thinking to deliver differentiated outcomes for both customers and business partners. Cornelius has an active membership to the UN Global Compact, ISO accredited for Quality Management (9001:2015), Environmental Management Systems (14001:2015) and Occupational Health and Safety Management (45001).
Follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250109291745/en/
Contacts
Federica Urso
Corporate Communications Director, EV Group
Mob. (+39) 338 7295116
@: mediarelations@eigver.it
Miriam Bolzoni
PR & Media Relations, EV Group
@: mediarelations@eigver.it
Caroline Sharp
Market Insights & Communication Manager, Cornelius Group
@: Caroline.Sharp@Cornelius.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody18.6.2026 02:01:00 EEST | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumour toxicities. Together, the companies will aim to develop a novel, tumour-selective therapeutic targeting a solid tumour antigen expressed across multiple difficult-to-treat cancer types. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615992992/en/ “Partnering with LG Chem represents a very important moment for LabGenius and provides further validation of our platform’s ability to design highly optimised multispecific antibodies,”said Dr. James Field, CEO of LabGenius. “We welcome this opp
Joe Vernachio Named President of SOREL18.6.2026 01:00:00 EEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Joe Vernachio will be the next President of SOREL. Founded in 1962, SOREL is a leader in functional and lifestyle footwear that can be worn anywhere from the tundra to the streets of New York City. “We’re excited to welcome Joe Vernachio back to the Columbia Sportswear family,” said Tim Boyle, CEO and Chair of the Board. “Joe is a terrific leader who can build on the great work, talent and momentum in place at SOREL.” Mr. Vernachio led the Mountain Hardwear brand for several years, until he left to become the COO and ultimately, the CEO of Allbirds. His background also includes time as Global Vice President for Product and Operations at The North Face, and key roles at Nike, Spyder, Roots, Calvin Klein and Patagonia. “Joe is a consumer‑focused, collaborative leader with a deep passion for product and brand storytelling. His energy, experti
Venture Global and EnBW Announce New LNG Purchase Agreements17.6.2026 23:30:00 EEST | Press release
Today, Venture Global, Inc. (NYSE: VG) and EnBW announced the execution of new, binding agreements for the purchase of approximately 0.82 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for approximately five years commencing in 2026, to be supplied from Venture Global’s portfolio. The new agreements add to the existing long-term sales and purchase agreements (SPAs) between Venture Global and EnBW for 2 MTPA for 20 years. “As one of Germany’s top LNG suppliers, Venture Global is proud to strengthen our partnership with EnBW and support the region’s energy security with a reliable supply of LNG,” said Venture Global CEO Mike Sabel. “The new mid-term agreements build on our strong, long-standing relationship with EnBW and reflects our commitment to meeting our customers’ evolving energy needs. Our dynamic marketing platform uniquely positions us to provide supply solutions across the short, medium, and long term.” About Venture Global Venture Globa
Kinaxis Announces Results of Voting at Annual and Special Meeting of Shareholders17.6.2026 23:05:00 EEST | Press release
Kinaxis® Inc. (“Kinaxis” or the “Company”) (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, received approval for all resolutions put forward to shareholders at today’s Annual and Special Meeting of Shareholders (the “Meeting”), as detailed in the Company’s management information circular dated May 5, 2026 (the “Circular”). 1. Election of Directors Shareholders voted to elect all eight directors nominated to the Kinaxis board, to hold office until the close of the next annual meeting of shareholders of the Company or until their successors are elected or appointed. Name of Nominee Total Number of Votes For Percentage of Votes For Total Number of Votes Against Percentage of Votes Against Razat Gaurav 21,870,163 99.01% 219,468 0.99% Robert Courteau 20,882,945 94.54% 1,206,685 5.46% Gillian (Jill) Denham 21,474,486 97.22% 615,143 2.78% José Alberto Duarte 21,699,181 98.23% 390,448 1.77% Lynn Loewen 21,952,244 99.38% 137,387 0.62% Angel Mendez 21,410,402 96
SES Announces Results of the Extraordinary General Meeting of Shareholders17.6.2026 20:23:00 EEST | Press release
SES (the “Company”) held an Extraordinary General Meeting (“EGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions. In particular, shareholders approved the cancellation of shares repurchased under the Company’s share buyback program of 2 November 2023, as amended on 2 May 2024, resulting in a corresponding reduction of the Company’s share capital. Shareholders also approved amendments to the Company’s articles of association, including indemnification for Board members and executives, as well as updates relating to the conduct of shareholder meetings. Detailed results on all matters voted on at the EGM will be available on the company’s webpage: https://www.ses.com/company/investors/shareholder-information/general-meeting-shareholders Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom